Skip to main content

Advertisement

SpringerLink
Log in

Unresolved issue: should patients with RA and a history of malignancy receive anti-TNF therapy?

  • Viewpoint
  • Published:

From Nature Clinical Practice Rheumatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bernatsky S et al. (2006) Malignancy and autoimmunity. Curr Opin Rheumatol 18: 129–134

    Article  Google Scholar 

  2. Gridley G et al. (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85: 307–311

    Article  CAS  Google Scholar 

  3. Mellemkjaer L et al. (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32(Part A): 1753–1757

    Article  Google Scholar 

  4. Askling J et al. (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64: 1421–1426

    Article  CAS  Google Scholar 

  5. Wolfe F and Michaud K (2004) Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50: 1740–1751

    Article  CAS  Google Scholar 

  6. Geborek P et al. (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64: 699–703

    Article  CAS  Google Scholar 

  7. Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275–2285

    Article  CAS  Google Scholar 

  8. Setoguchi S et al. (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54: 2757–2764

    Article  CAS  Google Scholar 

  9. Kress S (online December 24 2002) Adalimumab–for use in rheumatoid arthritis. [www.fda.gov/ohrms/dockets/AC/03/briefing/3930B1_01_C--HUMIRA.Med.Review.pdf] (accessed 18 January 2007)

  10. Watson KD et al. (2006) Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): results from the BSR biologics register [abstract]. Ann Rheum Dis 65 (Suppl): S512

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. A Brar is a Rheumatology Fellow and T Hiebert is an Internal Medicine Resident at the University of Manitoba, and H El-Gabalawy is Professor of Medicine and Immunology Director at the Arthritis Centre, University of Manitoba, Winnipeg, Canada.,

    Adarshdip Brar, Timothy Hiebert & Hani El-Gabalawy

Authors
  1. Adarshdip Brar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy Hiebert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hani El-Gabalawy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hani El-Gabalawy.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brar, A., Hiebert, T. & El-Gabalawy, H. Unresolved issue: should patients with RA and a history of malignancy receive anti-TNF therapy?. Nat Rev Rheumatol 3, 120–121 (2007). https://doi.org/10.1038/ncprheum0434

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0434

  • Springer Nature Limited

This article is cited by

Search

Navigation